Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) announced on May 1, 2026 that it granted inducement awards to 43 new employees under its 2024 Inducement Plan.

The awards are time-based RSUs totaling 208,850 shares, vesting one-third annually over three years, and were approved under Nasdaq Listing Rule 5635(c)(4) by the compensation committee.

News Market Reaction – NTLA

+4.60%

5 alerts

+4.60% Session close to close

$1.56B Market Cap

0.1x Rel. Volume

In the May 4 session, NTLA gained 4.60%, reflecting a moderate positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement RSU grants covering 208,850 shares for 43 new employees under t...

Analysis

This announcement details inducement RSU grants covering 208,850 shares for 43 new employees under the 2024 Inducement Plan, with vesting over three years and issued under Nasdaq Listing Rule 5635(c)(4). It follows a cluster of major clinical, regulatory and financing updates in late April 2026. Investors may track how ongoing hiring, equity compensation usage and future clinical or regulatory milestones interact with the company’s share count and execution strategy.

Key Figures

New employees: 43 employees Inducement RSUs: 208,850 shares Vesting schedule: One-third annually over 3 years +1 more

4 metrics

New employees 43 employees Recipients of inducement equity grants on May 1, 2026

Inducement RSUs 208,850 shares Aggregate RSUs granted under 2024 Inducement Plan

Vesting schedule One-third annually over 3 years Time-based vesting of RSU inducement awards

Plan adoption date June 2024 Initial adoption of Intellia’s 2024 Inducement Plan

Historical Context

5 past events · Latest: Apr 29 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	Equity offering pricing	Negative	-5.7%	Pricing of common stock offering at $10.75 per share with gross proceeds.
Apr 27	Equity offering announcement	Negative	+1.2%	Announcement of proposed $150 million common stock offering under shelf.
Apr 27	Phase 3 trial results	Positive	-4.3%	Positive Phase 3 HAELO results for lonvo-z in hereditary angioedema.
Apr 27	BLA submission update	Positive	-4.3%	Initiation of rolling BLA submission to FDA for lonvo-z in HAE.
Apr 24	Data timing announcement	Neutral	-4.3%	Notice of upcoming Phase 3 HAELO topline data and webcast date.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news shows repeated divergences: positive clinical and regulatory milestones, as well as an offering announcement, often coincided with negative price reactions, while one offering-related headline saw a modest gain.

Recent Company History

Over the past week, NTLA issued multiple major updates. On April 27, 2026, it reported positive Phase 3 HAELO results and a rolling BLA for lonvo-z, yet the stock moved about -4.33%. Around the same time, the company announced and then priced a common stock offering, with reactions of +1.23% and -5.72%. Ahead of the Phase 3 readout, an April 24 topline-data timing announcement also aligned with a -4.33% move. Today’s inducement grants occur against this backdrop of intense clinical and financing activity.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement grants, +1 more

5 terms

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate..."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"These awards were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grants financial

"it awarded inducement grants to 43 new employees under Intellia’s 2024 Inducement Plan..."

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

equity incentive plans financial

"awards were granted outside of Intellia’s stockholder-approved equity incentive plans..."

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 208,850 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com

FAQ

What did Intellia (NTLA) announce on May 1, 2026 about inducement grants?

Intellia announced inducement RSU grants to new hires totaling 208,850 shares. According to the company, the grants were awarded to 43 new employees under the 2024 Inducement Plan and approved by the compensation committee as material inducements to employment.

How many shares and what vesting schedule were included in Intellia's NTLA inducement grants?

The inducement grants total 208,850 restricted stock units with a three-year vesting schedule. According to the company, one-third of the RSUs vest annually over three years, subject to continued service through each vesting date.

Why were Intellia's (NTLA) awards granted under the 2024 Inducement Plan instead of existing equity plans?

The awards were granted outside stockholder-approved plans as permitted by an inducement plan. According to the company, the 2024 Inducement Plan was adopted by the board and amended to allow these material inducements under Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement grants in Intellia's NTLA announcement and who approved them?

A total of 43 new employees received inducement RSU grants. According to the company, Intellia’s compensation committee approved the awards on May 1, 2026, as material inducements to entering employment with Intellia.

Do Intellia's (NTLA) inducement RSUs vest immediately or require continued service?

The RSUs require continued service to vest and do not vest immediately. According to the company, vesting is time-based with one-third of the RSUs vesting each year over a three-year period, contingent on continued employment or service.